ESMO 2022 – Great oaks grow from small acorns: oncology is committed to doing its part for sustainability

PARIS, Sept. 9, 2022 /PRNewswire/ — At ESMO 2022, 9-13 September, Paris, France, the premier most cancers congress in Europe, which has gathered 28k individuals from 167 nations, many discussions can be round sustainability, prevention and novel approaches which might quickly turn into a actuality within the clinic.

• Late-breaking outcomes elucidate the hyperlink between air air pollution and lung most cancers in individuals who have by no means smoked
  
  “Pollution has a known association with lung cancer, but we didn’t know if and how it directly causes the disease” – Scientific Co-chair Charles Swanton, Francis Crick Institute, UK. These outcomes start to clarify how environmental carcinogens can drive most cancers, deriving a public well being mandate to decrease the degrees of those pollution, produced by the combustion of fossil fuels. “We have to achieve a 50% reduction in greenhouse gas emissions by 2030, by doing so we will naturally reduce levels of PM2.5. We can all play a part: we need to cycle more, walk more. PM2.5 cause 8 million deaths a year, not just due to cancer but also to other diseases, i.e., more than the deaths caused by tobacco globally.”
• Study confirms accuracy of multi-most cancers early detection blood testing, probably main to main paradigm shift in screening and early detection
  
  “This is one of the very first studies where the detection of cancer DNA in the blood has allowed to detect cancer at an early stage” – Scientific Co-Chair Fabrice André, Gustave Roussy, France. “If this test works, in the future it will be good news for patients. But with this comes a wake-up call for hospitals to see what will happen in 10 years and start now to train fellows and change infrastructures accordingly.”
• Other extremely anticipated outcomes to be introduced on the ESMO Congress 2022
  
  Phase III trial of first-in-class drug concentrating on a brand new molecular alteration in a uncommon class of cancers; landmark trial of cell remedy utilizing tumour-infiltrating lymphocytes to enhance outcomes for superior melanoma; a number of late-section trials of immunotherapy, together with for non-small cell lung most cancers not eligible to customary chemotherapy; research for underrepresented affected person populations

Full story: https://bit.ly/3B2pJ2f 

For extra: [email protected]

#ESMO22

ESMO is the main skilled organisation for medical oncology, with 25k members representing oncology professionals in 160 nations worldwide 

www.esmo.org   



Contact:

Vanessa Pavinato

+41 91 973 19 01

[email protected]

Source link